Gilead execs flag trial failures for Sjögren’s and lupus drugs — while cutting one analyst’s favorite HIV therapy

There’s more bad news on the Sjögren’s disease front today, after Gilead execs acknowledged in their Q3 call with analysts that their trio of drugs — including their top pipeline drug filgotinib — had failed mid-stage tests.

Click to view original post